U.S. Medical Equipment Stock News

Medicine worth an estimated £480m is reportedly wasted each year in England, which puts a harsh spotlight on how prescriptions are written, supplied and used. That kind of leakage can reshape where money flows across healthcare technology. Investors watching digital health and pharmacy platforms may not want to sit this out. This article looks at three Healthcare Technology Providers stocks exposed to this debate and explains why they might matter for your watchlist. The stocks covered below...

PureCycle Technologies stock added 4.9% to close at US$7.21 heading into the first full trading day after its Q2 2026 release. That is a confident move for a company that just reported another heavy quarterly loss. The market is cheering the balance sheet story instead of the income statement. The headline this quarter is liquidity. PureCycle raised about US$432m in fresh equity and convertible notes and finished the quarter with US$236.9m in total liquidity, plus an undrawn US$200m revolving...

Cryoport stock quietly entered this earnings day with a flat week and a slightly soft month, yet it closed up 2.8% at US$15.12 once the numbers were released. That move came against a mixed backdrop for a company still priced at a premium P/S multiple and not yet profitable. The main headline is straightforward. Cryoport reported Q2 revenue of US$49.0m and, importantly for a loss-making life sciences logistics business, delivered positive adjusted earnings before interest, tax, depreciation...

Puma Biotechnology stock jumped 9.7% to US$8.91 after earnings, a sharp move for a small oncology player that investors usually treat with caution. The immediate catalyst was simple: the company stayed profitable and lifted full year guidance, powered by NERLYNX net product revenue of US$53.6m and Q2 net income of US$8.2m. The bigger story is less about one quarter and more about whether this profit trend can coexist with forecasts for weaker earnings in the years ahead. That tension between...

The market barely flinched at Core Natural Resources today. The stock slipped only 0.4% even though Q2 delivered a sharp swing back into profitability, with basic earnings per share of US$2.51 and net income of US$126.5m. That kind of reset in an energy producer usually triggers a stronger emotional reaction than a flat tape. Right now traders seem more focused on the elevated P/E of 45.1x than on the earnings recovery. The sentiment story is a tug of war between valuation anxiety on one side...

The market just knocked Akamai Technologies down almost 7% in a single session, yet the story behind the earnings is more about profit pressure than a broken growth pitch. Coming into this report the stock had already slipped over the past quarter, so expectations were not euphoric. The headline today is that heavy cloud infrastructure spending and higher operating costs are squeezing margins even as revenue reached about US$1.10b. For an investor, the immediate question is whether this...

Turtle Beach stock jumped 11.2% today, but the headline from these earnings is not a growth surge. The company is still loss making on a trailing basis, but Q2 showed a sharp reset in how it earns each gaming dollar. Reported gross margin hit 38.8%, helped by tariff refunds, and even the underlying margin moved into the low 30s, which is a meaningful shift for a gaming accessories maker. The mood swing in the share price reflects investors treating this margin story as a turning point. The...

INNOVATE walked into this earnings season priced like a problem stock. The shares had barely moved over the past quarter and traded at a very low 0.1x price to sales. Then Q2 landed and the stock rose 63% in a single session after the release, as the company swung to a quarterly profit. The key takeaway is straightforward: INNOVATE generated Q2 revenue of US$421.6m and reported basic earnings per share of US$0.78, a sharp turn from recent losses. That profit result, alongside strong adjusted...

Voyager Therapeutics traded 4.5% higher to about US$3.27 after its latest quarter, a modest bounce for a biotech stock that has seen the share price fall over the past month and quarter. The move came even as Voyager reported another sizeable quarterly loss, with basic earnings per share at roughly US$0.40 in the red and net income again deeply negative. The real story for long term investors sits beyond this single print. Revenue expectations, balance sheet strain and the short cash runway...

Natera stock exploded higher, jumping about 21% in regular trading, as investors reacted to a quarter that leaned hard into growth and improving economics rather than clean profitability. The company posted Q2 2026 revenue of about US$752.8m and processed roughly 1,044,000 tests, with oncology and other molecular diagnostics products doing much of the heavy lifting. Loss per share narrowed to about US$0.47. For a company long treated as a high‑growth, high‑burn bet in molecular diagnostics,...

The market punished Transcontinental Realty Investors with an 8.4% one day drop, yet the headline from this quarter is not collapsing revenue. The real story is a sharp swing from a small profit in Q1 to a loss in Q2, even as revenue stayed near US$12.9m. That turn in earnings comes against a backdrop of rich valuation, with the stock trading on a P/E of 39.4x while a discounted cash flow estimate sits well below the current price. The gap between sentiment, price and fundamentals is where...

KVH Industries came into this earnings print with the stock already under pressure, down about 19% over three months, and the selling pressure continued as the share price slipped another 3% to US$8.03 after the release. That reaction sits awkwardly next to the headline result. Revenue in Q2 reached US$33.7 million with service revenue at US$29.7 million, and adjusted earnings before interest, tax, depreciation and amortization of US$3 million highlighted that the real story this quarter is...

Covista stock jumped 13.5% to US$140.98 today, and the move was all about margins. Investors responded to a full year adjusted EBITDA margin of 26.7% and a Q4 margin of 25.3%, both paired with Q4 revenue of US$501.4m. The share price reaction suggests traders are focusing on this as not just an enrollment story but also a profitability one. The question now is whether that enthusiasm reflects a careful reading of the numbers or a momentum-driven response to one strong year of margin gains...

Oscar Health came into this print with a mixed recent run, down over 10% in the past week and month but still sharply higher over the last quarter. The stock jumped about 5% today, and that move lines up with what the income statement just showed. Q2 delivered about US$4.9b in revenue and roughly US$362m in net income, reflecting the company’s shift to profitability. The real swing factor was profitability quality. Medical Loss Ratio and selling, general and administrative costs both moved in...

Cboe Global Markets (CBOE) is in focus after Cboe Clear Europe outlined plans to extend its Securities Financing Transactions clearing service into fixed income lending across major EU, Swiss, UK and US bond markets. See our latest analysis for Cboe Global Markets. The expansion of Cboe Clear Europe into fixed income lending comes after a busy few weeks for Cboe Global Markets, including second quarter earnings, an updated revolving credit facility and ongoing share repurchases. This...

Krispy Kreme stock ticked up 3.4% to US$3.34 into the close, which might look like a quiet vote of confidence. The earnings print was anything but quiet. The market is treating this as a small win, while the numbers point to a much larger tug of war between improving margins and an unprofitable core. The headline is margin repair. Adjusted earnings before interest, tax, depreciation and amortization jumped to US$28.8 million with margin at 8.7%, even as Krispy Kreme still reported a net loss...

Monte Rosa Therapeutics stock edged up about 1% after earnings, a modest move for a biotech that many investors view as a high risk, high reward pipeline story. The headline this quarter is the squeeze on the income statement. Q2 revenue came in at about US$9 million while the company reported a net loss of roughly US$43 million and a loss per share of about US$0.43. For a stock that has fallen sharply over the past month, the market reaction suggests investors were braced for pain and are...

USA TODAY stock just took a 9% hit to close at $7.25, capping a tough stretch that has the shares down over the past week and month. Yet behind that red screen sits an earnings story that is less about a single quarter and more about what you think the next few years look like. Q2 delivered $536.3 million in revenue and a second straight quarter of positive net income at $9.1 million. The stock trades at roughly 0.5x sales and far below one discounted cash flow estimate of fair value. Short...

The market barely flinched at Installed Building Products’ latest earnings, with the stock up less than 1% around US$244. That muted move sits awkwardly against a quarter that put one issue front and center for investors: the valuation premium is now harder to ignore. Installed Building Products is trading on a trailing P/E of 25.7x against lower industry and peer multiples, while earnings over the past year moved only slightly. Q2 did deliver higher revenue of US$777.8m and basic EPS of...

PENN Entertainment reported its second-quarter 2026 results, with revenue rising to US$1.86 billion and net income improving to US$33.1 million, turning around from a loss a year earlier. The quarter also brought record retail revenue, stronger margins, and a raised full-year outlook, while the interactive division narrowed its losses and adjusted its revenue expectations. Now we will examine how PENN’s earnings beat and upgraded full-year outlook influence its pre-existing investment...

In August 2026, ANI Pharmaceuticals reported second-quarter 2026 results showing sales of US$266.04 million and net income of US$24.71 million, alongside reaffirmed full-year net revenue guidance of US$1.08 billion to US$1.14 billion. The sharp year-on-year increase in quarterly earnings per share from continuing operations, on both a basic and diluted basis, highlights how recent performance is tracking against the company’s previously issued full-year outlook. Now we’ll assess how this...

Privia Health Group stock inched up 2.1% to US$22.45 after its Q2 print, a modest move for a company investors have punished over the past month with a slide of about 17%. The market’s first take looks cautious, yet the headline from this quarter is clear. Revenue reached US$632.6m and adjusted EBITDA climbed to US$37.4m, with management lifting full year guidance and pointing to improving margins. For anyone looking beyond today’s quote, the story now turns to whether those margins and cash...

Denali Therapeutics reported past second-quarter 2026 results with US$3.6 million in revenue, a net loss of US$127.55 million, and a reduced loss per share of US$0.68 from continuing operations compared with the prior year. Beyond the headline loss, the company’s first full-quarter commercial revenue from AVLAYAH, expanded payer access, and pro forma cash exceeding US$1.10 billion underscore a growing operational and financial platform for its neurology and rare disease pipeline. We’ll now...

Tandem Diabetes Care stock came into this earnings season on a tear, with the shares already sharply higher over the past month. Today the move turned into a jolt, as the stock jumped another 19% to US$22.38 after the Q2 print. The headline is clear: revenue reached US$254.56m and the company again reported a loss, yet investors locked on to one thing. The market is treating margin repair as the story that matters. Gross margin reached 57%, one of the highest levels Tandem Diabetes Care has...